Challenges and Opportunities to Develop Enediyne Natural Products as Payloads for Antibody-Drug Conjugates [0.03%]
enr苷类天然产物作为抗体药物偶联物载荷的挑战与机遇
Ajeeth Adhikari,Ben Shen,Christoph Rader
Ajeeth Adhikari
Calicheamicin, the payload of the antibody-drug-conjugates (ADCs) gemtuzumab ozogamicin (Mylotarg®) and inotuzumab ozogamicin (Besponsa®), belongs to the class of enediyne natural products. Since the isolation and structural determination...
An IgA mimicry of IgG that binds Polymeric Immunoglobulin Receptor for mucosa transcytosis [0.03%]
一种IgA模拟的IgG与聚合型免疫球蛋白受体结合用于黏膜跨细胞转运的新机制
Changchuin Mao,Richard Near,Varuna Shibad et al.
Changchuin Mao et al.
Most pathogens establish infection through mucosa, where secretary IgA (sIgA) plays an "immune exclusion" role in humoral defense. Extravasation of intravenously administrated therapeutic IgG mainly relies on convection and/or FcRn-mediated...
Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment [0.03%]
靶向肿瘤微环境中CD47功能的治疗性抗体的临床前和临床开发
Sukhbir Kaur,Kyle V Cicalese,Rajdeep Bannerjee et al.
Sukhbir Kaur et al.
CD47 is a ubiquitously expressed cell surface glycoprotein that functions as a signaling receptor for thrombospondin-1 and as the counter-receptor for signal regulatory protein-α (SIRPα). Engaging SIRPα on macrophages inhibits phagocytos...
COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19 [0.03%]
抗击冠状病抗体药物疗法追踪器：一个有关预防和治疗冠状病毒疾病的全球在线抗体药物数据库
Lifei Yang,Weihan Liu,Xin Yu et al.
Lifei Yang et al.
Facing the COVID-19 global healthcare crisis, scientists worldwide are collaborating to develop prophylactic and therapeutic interventions against the disease. Antibody therapeutics hold enormous promise for the treatment of COVID-19. In Ma...
Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications [0.03%]
2019年美国圣迭戈抗体工程与治疗大会亮点：双特异抗体设计及临床应用
Yong Zhu,Run Shen,Rui Hao et al.
Yong Zhu et al.
Although there are only two bispecific antibody (bsAb) drugs in the market, around 100 bsAb drug candidates are in clinical development. BsAbs have gained fast growing investment and attractions from the biopharmaceutical industry and acade...
Perspectives on the development of neutralizing antibodies against SARS-CoV-2 [0.03%]
针对SARS-CoV-2中和抗体发展的思考
Mitchell Ho
Mitchell Ho
SARS-CoV-2 gains entry to human cells through its spike (S) protein binding to angiotensin-converting enzyme 2 (ACE2). Therefore, the receptor binding domain (RBD) of the S protein is the primary target for neutralizing antibodies. Selectio...
Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function [0.03%]
巨噬细胞检查点阻断：来自临床试验的初步结果、结合分析和CD47-SIRPα结构功能研究
AbdelAziz R Jalil,Jason C Andrechak,Dennis E Discher
AbdelAziz R Jalil
The macrophage checkpoint is an anti-phagocytic interaction between signal regulatory protein alpha (SIRPα) on a macrophage and CD47 on all types of cells - ranging from blood cells to cancer cells. This interaction has emerged over the la...
Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy [0.03%]
用于识别DKK2线性表位及生成癌症治疗中和单克隆抗体的肽理性设计
Rongqing Zhao,Qian Xiao,Maohua Li et al.
Rongqing Zhao et al.
Dickkopf-related protein 2 (DKK2)is a member of the Dickkopf family in Wnt signaling pathway. Recently, we found that antibodies against DKK2 could activate natural killer (NK) and CD8+ T cells in tumors and inhibit tumor growth. In this pa...
Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display [0.03%]
利用蛋白质免疫和噬菌体展示技术分离兔源B7-H3单域抗体
Ruonan Feng,Ruixue Wang,Jessica Hong et al.
Ruonan Feng et al.
Single domain antibodies have certain advantages including their small size, high stability and excellent tissue penetration, making them attractive drug candidates. Rabbit antibodies can recognize diverse epitopes, including those that are...
[This corrects the article DOI: 10.1093/abt/tby012.][This corrects the article DOI: 10.1093/abt/tbz001.]. © The Author(s) 2019. Published by Oxford Univ...
Published Erratum
Antibody therapeutics. 2019 Jan;2(1):44. DOI:10.1093/abt/tbz006 2019